# A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

> **NCT07300150** · PHASE1 · RECRUITING · sponsor: **PAQ Therapeutics, Inc.** · enrollment: 195 (estimated)

## Conditions studied

- Colorectal Cancer
- Pancreatic Cancer
- Non-Small Cell Lung Cancer
- Solid Tumor

## Interventions

- **DRUG:** PT0511
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT07300150
- **Lead sponsor:** PAQ Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-21
- **Primary completion:** 2028-10-18
- **Final completion:** 2028-10-18
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07300150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07300150, "A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07300150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*